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บทคดัยอ่ 
ยนีไซโตโครม พ ี450 1 เอ 1 (CYP1A1) เป็นยนีเป้าหมายสาํคญัหน่ึงของ
มะเรง็ เน่ืองจากมหีน้าทีห่ลกัในการเปลีย่นแปลงทางชวีภาพของสารกลุ่ม 
polycyclic aromatic hydrocarbon (PAHs) ใหอ้ยูใ่นรปูสารกึง่กลางจาํพวก 
epoxide หรอืสารก่อมะเรง็ทีม่ฤีทธิส์งูสุดซึ่งสามารถกระตุ้นกระบวนการ
กลายพนัธุ์ในสายดเีอ็นเอที่เกี่ยวขอ้งกบัการเกดิมะเรง็ได้ mRNA ของ 
CYP1A1 จะถูกเหน่ียวนําใหเ้พิม่ขึน้ดว้ยการกระตุ้นการจบัระหว่างตวัรบั 
aryl hydrocarbon (AhR) กบั ligand)ไดแ้ก่ สาร PAH ทีม่อีนุพนัธ์ของ 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) เป็นสารต้นแบบ จากนัน้
สารประกอบของตวัรบั AhR และ ligand จะผ่านเขา้สูนิ่วเคลยีสอนัเป็นจดุ
เริม่การกระตุ้นยนี CYP1A1 ดงันัน้การรบกวนกลไกการควบคุมใด ๆ จะ
สง่ผลต่อกระบวนการเจรญิเตบิโตของเซลล์มะเรง็ ยิง่ไปกว่าน้ีการเพิม่การ
ทาํงานของ protein kinase C (PKC), tyrosine kinase และการกระตุน้ 
mitogen-activated protein kinases (MAPKs) จะสง่ผลใหเ้พิม่การส่ง
สญัญาณของตวัรบั AhR นอกจากน้ี glucocorticoid receptor (GR) และ 
estrogen receptor (ER) ยงัแสดงผลร่วมต่อกระบวนการสง่สญัญาณของ
ตวัรบั AhR ได ้อาท ิ GR  สามารถลดการแสดงออกของยนี CYP1A1 ที่
แสดงผลผ่านกลไกของตวัรบั AhR โดยจบักบัองคป์ระกอบของตวัรบั AhR 
หรอืองค์ประกอบภายในยนีที่ตอบสนองต่อสารแปลกปลอม (xenobiotic 
responsive element) ในขณะที ่ER สามารถสง่ผลโดยตรงต่อสว่นโปรโม
เตอรภ์ายในยนี CYP1A1 โดยเป็นเสมอืนตวัควบคุมร่วมในการเหน่ียวนํา
ผ่านตวัรบั AhR ในสภาวะปกติตวัรบั AhR มบีทบาทส่งเสรมิการ
เจรญิเตบิโตของเซลลแ์ต่ตวัรบั AhR สามารถแสดงผลตรงกนัขา้มในสภาวะ
ทีม่ลีแิกนด์ เน่ืองจากยนี CYP1A1 สามารถพบไดใ้นเน้ือเยื่อหลายชนิด 
เช่น ปอด รก ตบัและไต แมว้่าจะพบยนีน้ีในตบัเมื่อถูกเหน่ียวนําด้วยสาร
กระตุน้ต่าง ดงันัน้กระบวนการเจรญิของมะเรง็ทีเ่กีย่วขอ้งกบัการแสดงออก
ทีม่ากเกนิไปของยนี CYP1A1 จงึมโีอกาสเกดิขึน้ในอวยัวะหลายชนิดจาก
การได้ร ับลิแกนด์ภายนอกที่ปนเ ป้ือนอยู่ทัว่ไปในสภาวะแวดล้อม 
นอกจากน้ีความหลากหลายทางพนัธุกรรมของยนี CYP1A1 พบว่าสมัพนัธ์
กบัโอกาสเกดิมะเรง็หลายประเภทดว้ย  
คาํสาํคญั: ยนีไซโตโครม พ ี 450 1 เอ 1, ตวัรบัแอรลิไฮโดรคารบ์อน, 
มะเรง็, AhR  
 
Abstract 
CYP1A1 gene is an important target in cancer, due to its role in 
metabolic bioactivation of polycyclic aromatic hydrocarbons (PAHs), 
to electrophilic intermediates referred to bay region epoxides, to 
ultimate carcinogens and capable of causing oncogenic mutations in 
DNA. Expression of CYP1A1 mRNA is elevated by activation of the 
arylhydrocarbon receptor (AhR) through binding of exogenous 
ligands such as PAHs, of which the halogenated derivative 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) is a prototype, then translocates 
from cytoplasm to nucleus upon the activation. Hence, disruption of 
these regulatory pathways is implicated in tumor progression. In 
addition, up-regulation of protein kinase C (PKC) and tyrosine 
kinase, as well as activation of mitogen-activated protein kinases 
(MAPKs) result in increase of AhR signal transduction. 
Glucocorticoid receptor (GR) and estrogen receptor (ER) also affect 
AhR-mediated pathway, but undergoing via different aspects. 
Namely, GR decreases AhR-mediated expression by interacting with 
xenobiotic responsive element-binded AhR, while ER has a direct 
interaction with CYP1A1 promotor by acting as a co-regulator of 
AhR-mediated transcriptional activation. In normal condition, AhR 
plays a promoting role in cell cycle progression. In the existence of 
exogenous ligands, AhR shows inhibitory effect vice vesa. CYP1A1 
is expressed constitutively in several extrahepatic tissues such as 
intestine, lung, placenta, and kidney, but not in liver. However, 
CYP1A1 expression has been demonstrated in the liver after inducer 
treatment. Therefore, cancer progression regarding overexpression 
of CYP1A1 possibly occurred in several organs related to exogenous 
ligands in every day exposures, e.g. smoking, diet, and the 
environment. Apart from these, genetic polymorphism of CYP1A1 
gene has recently been noted to involve in difference types of 
cancer. 
 Key words: CYP1A1 gene, aryl hydrocarbon receptor, cancer, AhR 
 
Introduction
Among phase I biotransformation, cytochrome P450 
(P450) system ranks the first in catalytic versatility and the 
sheer number of xenobiotics it detoxifies or activates to 
reactive intermediates.1P450 is a microsomal superfamily of 
isoenzymes. All P450 enzymes are heme-containing 
proteins. The heme iron in P450 is usually in the ferric (Fe3+) 
state. When it is reduced to the ferrous (Fe2+) state, P450 
can bind ligands. P450 is located on the smooth 
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endoplasmic reticulum of cells throughout the body. P450 
enzymes are present in almost all tissues but the highest 
concentration of P450 enzymes is found in the 
endoplasmatic reticulum of the liver (microsomes).2 The liver 
microsomal P450 enzymes involve in xenobiotic 
biotransformation belong to three main P450 gene families, 
namely CYP1, CYP2 and CYP3. Liver microsomes also 
contain P450 enzymes encoded by CYP4 gene family, the 
substrates of which include several fatty acids and 
eicosanoids but relatively few xenobiotics. The level and 
activity of each P450 enzyme have been shown to vary from 
one individual to the next, due to environmental and genetic 
factors.3,4 In conclusion, cytochrome P450 enzymes play a 
dual role in the organism. On the one hand, they inactivate 
the drug/xenobiotic and prepare it for excretion. On the other 
hand, they are also capable of activating foreign chemicals 
to highly reactive toxic intermediates that might act as 
carcinogens or mutagens.  
 
Cancer 
Cancer continues to be a worldwide killer which is a 
complex disease where genetics, lifestyle, and environment 
play important roles indicating susceptibility to the disease. 
One defining feature of cancer is the uncontrolled growth 
because it has high cell proliferating rate and spread of cells. 
It can affect almost all part of the body. The growth often 
invades surrounding tissue and can metastasize to distant 
sites. Cancer arises from one single cell. The transformation 
from a normal cell into a tumor cell is a multistage process, 
typically a progression from a pre-cancerous lesion to 
malignant tumors. These changes are the result of the 
interaction between a person's genetic factors and external 
agents.5 Environmental factors are transmitted to the cell by 
different regulatory mechanisms.6 
 CYP1A1: Cancer progression. Chemical carcinogens 
in environment are mostly chemically inert by themselves 
and require metabolic activation by cytochrome P450 (CYP) 
enzymes to more reactive metabolites in order to exhibit 
carcinogenicity in experimental animals and humans.7 CYP1 
family plays major roles in metabolic activation of a variety of 
environmental carcinogens. CYP1A1, one of the three 
members of CYP1 family, principally involved in metabolizing 
polycyclic aromatic hydrocarbons (PAHs), to reactive 
electrophiles intermediates, and subsequently form 
carcinogenic DNA adduct.7 CYP1A1 is constitutively 
expressed in extrahepatic tissues, such as lung, kidney and 
placenta, and inducibly demonstrated in the liver after 
exposure to an inducer8, thus CYP1A1 contributes to the 
incidence of cancers in these organs, at least in part. 
Expression of the CYP1A1 gene is inducible in a ligand-
dependent fashion by the aryl hydrocarbon receptor (AhR), 
when PAHs and other carcinogens are ingested into an 
animal’s body9 leading to increasing synthesis of these 
enzymes.  
 
CYP1A1: Cancer prevention. It is widely accepted that 
CYP1A1 enzyme metabolically activates many PAHs, 
including benzo[a]pyrene (B[a]P), to DNA- and protein-
binding intermediates that are associated with toxicity, 
mutagenesis, and carcinogenesis. In contrast, study of the 
role of CYP1A1 in an intact animal showed that CYP1A1 
inducibility was essential in detoxication of oral B[a]P.10 
Therefore, the important role of CYP1A1 in the detoxification 
of environmental carcinogen became interesting according to 
many dietary compounds in the metabolic activation pathway 
to perform the cancer preventative activity.  
Conclusively, the expression of CYP1A1 as cancer 
progression or preventive may depend on the balance of 
procarcinogen activation, detoxication, and naturally dietary 
natural product-extrahepatic metabolism.11 The present 
review aims to comprehensively summarize about the 
bimodal roles of CYP1A1 in carcinogen-activating and 
cancer preventing.   
 
Mechanism of Procarcinogen 
Activation by CYP1A1 
CYP1A1 is responsible for activation of most 
carcinogenic polycyclic aromatic hydrocarbons (PAHs) to 
epoxide intermediates, which are further converted to more 
reactive diol-epoxides, i.e., 5-methylchrysene-1,2-diol, 
(+)benzo(a)-pyrene-7,8-diol, chrysene-1,2-diol, benzo(b)fluor-
anthrene-9,10-diol, etc., with aid of epoxide hydrolase.9 An 
important and very extensively studied prototype of PAHs 
widely accepted to demonstrate the activation process of the 
carcinogen is benzo[a]pyrene (B[a]P).  
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Metabolic activation of the prototype carcinogen B[a]P 
was extensively studied by the research groups of Jerina 
and Conney in the mid-1970’s.7 It was initially thought that 
B[a]P-4,5-epoxide, the so called K-region epoxide, was the 
ultimate carcinogenic metabolite.12 However, the B[a]P-4,5-
epoxide was found to be readily hydrolyzed by epoxide 
hydrolase to an inactive B[a]P-4,5-diol metabolite and was 
finally concluded not to play a major role in carcinogenesis 
by B[a]P.7 Subsequent investigation of several B[a]P 
metabolites revealed that the diastereomeric B[a]P-7,8-diol-
9,10-epoxides (Figure 1), commonly referred to as bay 
region epoxides, were highly reactive towards DNA. Hence, 
they were concluded as the ultimate carcinogenic meta-
bolites of B[a]P. The pathways leading to the formation of 
B[a]P bay region epoxides are as the following.  
 
 
Figure 1 Chemical structure of diastereomeric B[a]P-7,8-diol-
9,10-epoxides (Androutsopoulos et al, 2009).11 
 
B[a]P is firstly oxidized by liver microsomes of MC-
treated rats to (+)- and (-)-B[a]P-7,8 oxides, with the 
conversion rate of the (+) enantiomer being much higher 
than that of the (–) form. Subsequently, microsomal epoxide 
hydrolase rapidly hydrolyzes these oxides to produce (-)- 
and (+)-B[a]P-7,8-diol.13 Last step is oxidative activation of 
each of these metabolites by P450s to produce four diol 
epoxides (Figure 2), namely (-)-B[a]P-7,8-diol-9,10-epoxide-
1, (+)-B[a]P-7,8-diol-9,10-epoxide-2, (+)-B[a]P-7,8-diol-9,10-
epoxide-1, and (-)-B[a]P-7,8-diol-9,10-epoxide-2 respec-
tively14, which are highly mutagenic to Ames Salmonella 
tester strains and Chinese Hamster V-79 cells. Additionally, 
the epoxides are denoted as bay region epoxides due to 
their ability to cause oncogenic mutations in specific parts of 
the DNA.11     
 
 
 
 
 
 
 
 
Figure 2 Absolute stereochemistry of the optical enantiomers of 
the diastereomeric BP-7,8-diol-9,10-epoxides derived 
from BP-7,8-dihydrodiol (Buening et al, 1978).14 
 
The metabolite (+)-B[a]P-7,8-diol-9,10-epoxide-2 was 
identified as the most reactive of the four metabolites in 
producing tumors in newborn mice. This diol epoxide was 
considered to be the ultimate carcinogenic conversion 
product of B[a]P, because it had almost the same level of 
carcinogenicity as B[a]P itself and (-)-B[a]P-7,8-diol. This diol 
epoxide is considered to be the ultimate carcinogenic 
metabolite of B[a]P.7,15   
The bay region theory has also been applied to other 
PAHs to investigate their carcinogenic activation by CYPs 
and epoxide hydrolase and found the result as same 
metabolic activation pattern as B[a]P.7  
Other typical PAHs have been investigated for their 
carcinogenic actions and considered to be activated in 
accordance with the bay region theory including benz[a]-
anthracene, benzo[b]fluoranthrene, benzo[c]phen-anthrene, 
chrysene, benzo[g]chrysene and 5,6-dimethyl-chrysene and 
5-methylchrysene16 (Figure 3). Certainly, these reactive 
intermediates of PAHs dihydrodiols were activated selectively 
in in vitro by human recombinant CYP1A1 and CYP1B1 to 
DNA-modifying products in Salmonella typhimurium NM2009 
tester strain.17 The carcinogenic potential of CYP1A1 in the 
activation of PAHs has been investigated further in in vivo, 
according to its activation of aflatoxin B1 to 8,9-epoxide in 
rabbit lung and liver.18 In addition, B[a]P also induced 
carcinogenesis in mice which were positive for the aryl 
hydrocarbon receptor, AhR (+/+).19 Therefore, CYP1A1 in the 
activation of PAHs has many studies both in vitro and in 
vivo.  
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Figure 3 Structures of bay-region diol-epoxides of several poly-
cyclic aromatic hydrocarbons (Conney AH, 1982).7  
 
 
  
(A) (B) 
Figure 4 Relative quantification of (A) PhIP N2-hydroxylase 
activity and (B) PhIP-DNA adducts in lung 
homogenates of Cyp1a1-null mice, Cyp1a2-null mice, 
and wild type (WT) mouse (Ma & Whitlock, 1996)20 
 
 
AhR-Mediated CYP1A1 Induction 
The aryl hydrocarbon receptor (AhR) or dioxin receptor 
mediates the carcinogenic and other toxic effects of a variety 
of environmental pollutants, including an industrial byproduct 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and some poly-
cyclic aromatic hydrocarbons (PAHs)22. As a consequence of 
AhR activation, induction of CYP1A1 expression is also 
mediated through AhR.23 Unliganded AhR exists as a part of 
a cytosolic protein complex. There are two chaperone 
molecules of Hsp-90 heat-shock proteins, a co-chaperone 
protein called p23 and the immunophilin-like protein XAP2 
(hepatitis B virus X-associated protein 2).24 Entry of an 
exogenous ligand such as B[a]P or TCDD, through the cell 
membrane leads to binding to the receptor followed by 
translocation of the cytosolic heat-shock chaperone complex 
to the nucleus, various MAP kinases are involved in this 
step. The AhR undergoes dissociation from the chaperone 
proteins and heterodimerization with ARNT (aryl hydrocarbon 
nuclear translocator) that recruits p30023 (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 AhR ligand-mediated activation of phase I and II 
metabolizing enzyme genes (Conney, 19827; Westwell 
200425).  
 
The AhR-ARNT heterodimer binds to consensus 
regulatory sequences termed AhREs (aryl hydrocarbon 
response elements), XREs (xenobiotic response elements), 
or DREs (dioxin response elements), located in the promoter 
region of the CYP1A1 gene. In addition, AhR/ARNT 
heterodimer directly interacts with Sp1 and the two 
transcription factors (p300 and p/CIP) to synergistically 
enhance the expression of CYP1A1 gene which eventually 
leads to binding with TBP (TATA binding protein) and 
subsequent recruitment of RNA polymerase Il.26 Regarding 
induction of the CYP1A1 gene, TCDD causes a broad 
spectrum of biochemical and toxicological effects, and tumor 
promotion. This proposed mechanism of CYP1A1 induction 
also applies to certain Phase II xenobiotic metabolizing 
enzymes, such as NQO1 (NAD(P)H-dependent quinone oxy-
doreductase-1), UGT1A6 (UDP-glucuronosyl transferase), 
ALDH3A1 (aldehyde dehydrogenase) and several glutathi-
one S-transferases.27  
 
Interaction of AhR with Protein Kinase C, 
Tyrosine Kinases, and MAPK Kinases 
Phosphorylation regulates AhR activity in the physiol-
ogical signaling pathway regulating cell cycle progression as 
well as the xenobiotic signal transduction pathway. Recently, 
it has been found that modulation of the protein kinase C 
(PKC) pathway also affects AhR signaling. In addition, 
phosphorylation at the tyrosine residues of the carboxy 
terminal half of AhR is required for the formation of the 
functional AhR/ARNT heterodimer.23 Therefore PKC and 
tyrosine kinase are also involved in AhR signal transduction, 
as inhibitors of these kinases block the induction of target 
genes.23,28 The inhibition of PKC blocks ligand-activated DNA 
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binding of AhR/ARNT heterodimers and leading to a 
decreased Cyp1 gene expression.28 
Activation of MAPKs (mitogen-activated protein kinases) 
activities are becoming increasingly accepted in the AhR 
pathway because they are the members of the signal 
transduction system involved in the control of gene 
expression and various events in eukaryotic cells.29 MAPKs 
family, comprises of the ERK and JNKs, along with the p38s, 
are seine and threonine protein kinase which can 
phosphorylate a large panel of substrates on these residues 
directly to transcriptional factors or via down-stream MAPK-
activated protein kinases.23  
The interplay between MAPKs and AhR is modulated by 
various exogenous stimuli; an example of them is UV 
radiation which activates p38, JNK, and ERK kinases. The 
activation of MAPKs and parallel formation of tryptophan 
photoreactive products leads to increased expression of 
CYP1 genes.29 In addition, the up-regulation of ERK and 
JNK by three AhR ligands, TCDD, B[a]P, and benzo[a]-
pyrene-diolepoxide (BPDE) performed in human lung 
carcinoma A549 cells and mouse hepatoma Hepa-1 cells 
critically link to the AhR activity and receptor-dependent 
gene expression. Similarly, inhibition of the ERK and JNK 
pathway using specific inhibitors completely blocked TCDD-
induced ERK, or JNK activation, respectively, and partially 
suppressed AhR activity and CYP1A1 induction. Most 
significantly, dual inhibition of ERK and JNK pathways 
caused nearly complete suppression of CYP1A1 induction.30 
Conclusively MAPK activation is a novel and generalized 
cellular response to xenobiotics. Many studies indicated that 
the MAPK pathways are important signaling mechanism 
involved in the activation of AhR, in TCDD toxicity, and 
possibly in B[a]P carcinogenicity.30  
AhR interaction is also present with other pathways. 
Glucocorticoid receptor (GR) both in vitro and in vivo, GR 
decreases AhR-mediated expressions by interacting with 
XRE-binded AhR. Decreased expression of P450s means 
prolonged half-life of some anti-cancer drugs or slower 
activation of procarcinogens.31 Cross talk of AhR and ARNT 
with the estrogen receptor  (ER) has also been 
established in a number of different systems32,33 and could 
be important in estrogen-related cancers. TCDD does not 
bind to ER, but it inhibits ER signaling. More importantly, 
ER plays a significant role in modulating AhR activity, as it 
has been reported by in vitro and in vivo studies that co-
treatment of TCDD and E2 resulting in an increased 
induction of CYP1A1, compared to TCDD treatment alone. 
ER has a direct interaction with the CYP1A1 promoter, 
suggesting that it acts as a co-regulator of AhR-mediated 
transcriptional activation34. The interaction of ER with AhR 
and ARNT has also been suggested35. It has been implied 
that both ER and ER can regulate expression of 
carcinogen-metabolizing genes such as CYP1A1. 
 
Role of AhR in Cell Cycle Progression 
Several published accounts point to a role for AhR in cell 
cycle control. Ma and Whitlock (1996)20 revealed that an 
AhR-defective cell exhibited a prolonged doubling time 
compared with its wild-type counterpart. This effect was 
attributed to delayed progress through the G1 phase.23 
These findings revealed that decrease of AhR content was 
also associated with decreased proliferation of mouse 
hepatoma (Hepa1c1c7) cells in culture.  
Another AhR promotes progression of the cell cycle as 
shown in mouse embryo fibroblasts (MEF) from AhR null 
mice were found to grow more slowly. The DNA synthesis 
rate was also markedly different by 24 hours, the wild-type 
MEF cultures had incorporated 3-fold more [3H]thymidine 
than the AhR-null MEFs. By 72 hours, the AhR-null MEFs 
incorporated only 35% of [3H]thymidine compared with the 
control cultures.36 These results indicated that in the 
absence of an exogenous ligand, the AhR promoted 
progression through the cell cycle.23  
There was extensive evidence in several different cell 
lines supporting the conclusion that exogenous AhR ligands, 
especially TCDD, actually inhibited cell proliferation and 
induced cell cycle arrest in normally cycling cell 
populations.37 TCDD also inhibited 17-estradiol-induced 
growth of MCF-7 human breast cancer cells38, and inhibited 
proliferation of the fish hepatocellular carcinoma PLHC-1 cell 
line39 and the androgen-induced proliferation of G0/G1-
synchronized human prostate cancer LNCaP cells.40  
The inhibition of cell cycle progression by AhR ligands 
was a direct interaction between the AhR and hypophospho-
rylated retinoblastoma (RB).23 The AhR formed complexes 
with the RB protein, then synergisting to repress E2F-
dependent gene expression (Figure 6A), which related to 
proteins such as cyclinE, DNA polymerase , and DHFR, 
leading to slow down the progression of cells from G1 into 
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S-phase41. In addition, AhR functioned as a co-repressor of 
RB, mediating repression of RB target genes, such as CDK2 
and cyclin A, to cause cell cycle arrest42 (Figure 6B). 
 
 
Figure 6 Role of the AhR in cell cycle regulation. (A) Under 
normal conditions and (B) under activation of AhR 
(Modified from www.interscience.wiley.com)  
 
These results suggested that the interaction between 
AhR and RB acted as a negative regulator of cell cycle 
progression by inhibiting E2F-dependent transcriptional 
activity. However, there has been found a significant 
increase in the expression of the CDK inhibitor p27kip1, 
indicating a positive regulatory mechanism involving up-
regulation of cyclin kinase inhibitors.23 In conclusion, the 
AhR, a potent transcriptional activator, may act as a 
repressor of transcription through the formation of specific 
protein–protein interactions36 (Figure 6B).  
Additional data showed other mechanisms to investigate 
the AhR role in cell cycle regulation in the absence of 
exogenous ligands. Use of integrated AhR variants in 
fibroblasts from AhR null mice showed that AhR+/+ 
fibroblasts significantly proliferated faster than AhR-/-  
fibroblasts, and exposure to TCDD did not change their 
proliferation rates.43 These findings indicated that AhR 
function in the cell cycle was ligand-independent.  
A recent study determined if constitutively active AhR 
affected the same transcriptional outcomes as environmental 
chemical-activated AhR.44 The results shown that the 
constitutively active AhR maintained high baseline levels of 
CYP1B1 in immortalized or malignant human breast cell 
lines, but little or no CYP1A1 was detected (Figure 7), 
whereas the AhR hyper-activation by TCDD activates both 
genes, which implies a contribution of AhR and CYP1B1 
prior to tumor formation44 (Figure 8). These two contradictory 
bodies of evidence implies the wider function of AhR in the 
presence and absence of a ligand.  
 
 
 
 
 
 
 
 
Figure 7 Preferential expression of CYP1B1 (A) in immortalized 
(MCF-10F) and (B) DMBA transformed, malignant 
(BP1) human breast epithelial cell lines(Yang et al, 
2008).44  
 
 
Figure 8 Hyper-activation of AhR with TCDD increased AhR 
binding to both CYP1A1 and CYP1B1 promoters, but 
not necessarily increase these gene expression (Yang 
et al, 2008).44  
 
CYP1A1 Expression 
CYP1A1 plays a major role as a carcinogen activating 
enzyme. Unlike most P450 enzymes, CYP1A1 is mainly 
expressed in extrahepatic tissues, especially lung, where it 
metabolizes and is markedly induced by PAHs.8,45 CYP1A1 
expression has been reported among 107 human lung 
adenocarcinoma, by which 48 and 29 of these were AhR 
high expressers, and expressed CYP1A1 respectively. After 
stratification by smoking status, the association between 
AhR and CYP1A1 was found only in smokers. These 
findings concluded that AhR and CYP1A1 expression was 
associated in smoking adenocarcinoma patients.46  
Another study showed the occurrence of methylation in 
the promoter of CYP1A1 associated with tobacco smoking, 
as lung samples from active smokers which lacked 
methylation of the CYP1A1 promoter exhibited slightly higher 
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pulmonary EROD activity, in the regression models for age 
and daily consumption of tobacco.47 In addition, the 
expression of CYP1A1 and AhR in small-cell lung carcinoma 
has been proposed as a putative diagnostic marker and has 
also been correlated with a history of cigarette smoking. 
CYP1A1 expression in lung tissues have largely influenced 
by the paradoxical induction of the enzyme from continuous 
exposure to the environmental chemicals.11 
A differential overexpression of CYP1A1 between tumor 
and normal cells, which can potentially lead to the various 
applications of the enzyme in cancer pathology and 
treatment, was explored. The most significant finding 
demonstrated that CYP1B1 as a tumor marker was 
expressed at a high frequency in a wide range of human 
cancers of different histogenetic types, and not detectable in 
normal tissues48 (Table 1). The same finding has drawn 
similar associations in CYP1A1, but in a smaller range of 
tumors, compared to CYP1B1.49  
 
Table 1 Expression of CYP1B1 in different types of malignant 
tumors and normal tissue48  
Tissue Normal# Tumor* 
Bladder 0/8 8/8 (transitional cell carcinoma) 
Brain 0/12 11/12 (astrocytoma) 
Breast 0/10 12/12 (invasive ductal carcinoma) 
Colon 0/10 11/12 (adenocarcinoma) 
Connective tissue 0/9 8/9 (sarcoma) 
Esophagus 0/8 8/8 (squamous carcinoma) 
Kidney 0/11 11/11 (clear cell carcinoma, n=10; transitional cell 
carcinoma, n=1) 
Liver 0/8 Not tested 
Lung 0/8 7/8 (squamous carcinoma) 
Lymph node 0/5 9/9 (non-Hodgin’s lymphoma) 
Ovary 0/5 7/7 (adenocarcinoma) 
Skin 0/5 6/6 (squamous carcinoma) 
Small intestine 0/5 Not tested 
Stomach 0/10 9/10 (adenocarcinoma) 
Testis 0/8 8/8 (malignant germ cell tumor) 
Uterus 0/7 7/7 (adenocarcinoma, n=5; malignant mixed 
Müllerian tumor, n=2) 
Total 0/130 122/127 
Note: # number positive/number tested; * number positive/number tested 
(histopathological diagnosis) 
 
CYP1A1 was presented to a greater extent in malignant 
than in normal breast.49,50 Oestradiol C-4 hydroxylase (4-OH-
E2) activity which is a marker of CYP1A1 activity was 
observed, since neoplastic mammary tissue involved in the 
metabolism of oestrogen51 (Figure 9). CYP1A enzyme was 
present in a small percentage of non-neoplastic samples of 
oesophageal tissue, whereas in oesophageal carcinomas the 
enzyme was expressed at least 60% of the samples.52 
Figure 9 Microsome-mediated formation of 2-OH-E2 (open bars) 
and 4-OH-E2 (solid bars) obtained fresh from human 
mammary fibroadenomas, adenocarcinomas, and 
normal tissue (Liehr & Ricci, 1996).51 
 
CYP1A was further detected in 68% of the urinary 
bladder tumors and its expression correlated with bladder 
tumor grade.53 These findings revealed that carcinogen-
activating role of CYP1A1 regard to the metabolism of PAHs 
and others exogenous substances from the continuous 
exposure lead to increased expression of the enzyme that 
well established carcinogen activity. CYP1A1 is the only 
placental xenobiotic metabolizing enzyme. It is well 
recognised in the bioactivation of many compounds critically 
in the first trimester, and then declines in the second and 
third trimestered. In addition, CYP1A1 expression in placenta 
involved with the substrate specificity towards oestradiol and 
the potential carcinogenic that can cause harmful effects 
during fetus developed54. Importantly, placental CYP1A1 is 
also involved in the bioactivation of many constituents in 
cigarettes, such as PAHs (B[a]P), lead to DNA-reactive 
species, and forming DNA adducts both in the placenta and 
fetal tissues. Therefore, significant induction of placental 
CYP1A1 activity in women exposed to cigarette smoke was 
extensively reported55. Choriocarcinoma cell line, Bewo, is a 
representative of human placenta to study the EROD activity 
assay in the presence of typical inducers (3-
methylcholanthrene, -naphthoflavone, and 1,2-benzanthra-
cene). The results shown that CYP1A1 was induced via an 
increase of EROD activity compared to the levels observed 
in the absence of any inducer56 (Figure 10). The same 
results were reported by Hakkola and colleagues.57 
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(A) (B) 
Figure 10 Induction of CYP1A1 (A) in either BeWo cells or 
primary cultures of human cytotrophoblasts micro-
somes after pretreatment with 3-MC or -NF (B) in 
BeWo cell microsomes after pretreatment of the cells 
with 1,2-benzanthracene (Avery et al, 2003).56 
 
CYP1A1 Polymorphisms 
Polymorphism is another important factor that determines 
expression of P450s in different tissues. For CYP1A1, each 
of the polymorphisms is given a number in order of 
publication, which followed the symbol*. Thus, CYP1A1*1 is 
the wild-type. Two major changes causing CYP1A1 
polymorphism are reported: the TC transition in the 3' 
non-coding region, which has been associated with elevated 
enzyme activity (Crofts et al, 1994), which introduces a new 
MspI restriction site or m1 polymorphism (CYP1A1*2A), and 
is found in 5% of Caucasians.58 The CYP1A1 Msp1 
polymorphism was found to be a significant factor in 
determining the risk of breast cancer among post-
menopausal Chinese women in Taiwan. The same results 
were found in African-American patients; however, this was 
not apparent in Caucasians.59 The second most commonly 
encountered CYP1A1 polymorphism involves an AG 
transition in exon 7, which introduces Ile462Val or m2 
polymorphism (CYP1A1*2C)59 resulting in the replacement of 
an isoleucine (Ile) by valine (Val), which leads to an amino 
acid substitution in the heme-binding region and results in an 
increase in microsomal enzyme activity.60    
Both CYP1A1 m1 and m2 polymorphisms are strongly 
associated with lung cancer especially in relation to tobacco 
smokers and in lung squamous cell carcinoma (SCC) in 
Japanese but not in Caucasian.61 These findings were not 
comfirmed in studied conducted in Caucasian population, 
where the prevalence of the CYP1A1 m1 and m2 alleles was 
very low62.However, larger studies in mixed American 
population point to an elevated risk of lung cancer in m1 
allele. In Brazillian populations increased in lung cancer risk 
was significantly associated with the presence of the m2 
allele.63 
The variant CYP1A1 m3 has a mutation in intron 7 and 
appear to be Afican-American specific. An elevated risk for 
lung adenocarcinoma among two populations was 
observed.64 Another polymorphism (m4) located two bases 
upstream of the m2 site, also causes an amino acid 
substitution of the TA in the heme binding region of the 
enzyme, but effect of this polymorphism on enzyme activity 
is not clear yet.63 Until now, the evidence referred to the 
association of genetic polymorphisms of CYP1A1 with 
cancer occurrence is still conflicting. Some studies have 
concluded that there is increase susceptibility to cancer in 
the presence of polymorphic variants, whereas others have 
reported no relationship between the two.65,66  
Although a large body of experimental results points 
towards a positive association of CYP1A1 genetic 
polymorphisms and cancer occurrence, the relative 
contribution of CYP1A1 polymorphisms to the entire process 
of chemical carcinogenesis still remains to be evaluated. 
Cancer susceptibility due to carcinogen exposure is probably 
determined by an individual phenotype for a number of 
carcinogen metabolizing enzymes and the genetic 
susceptibility factor only becomes relevant if sufficient 
exposure occurs. Further investigation is required for such 
findings to be extrapolated successfully to human 
populations.  
 
Conclusion 
CYP1A1 is an enzyme involved in activation of a number 
of carcinogenic PAHs to reactive electrophiles that initiate 
cell transformation. CYP1A1 expressed mainly in extra-
hepatic organs and are highly inducible by carcinogenic 
PAHs and TCDD through AhR which is responsible for the 
inducible expression of CYP1A1. Normally, AhR exists in 
inactive form within the cytoplasm in association with a 
complex of Hsp90, XAP2, and Hsp90 Co-chaperone p23. 
Upon ligand binding, AhR in the complex is activated, and 
then Hsp90 is released from the complex and the receptor 
translocates to the nucleus, where it forms a heterodimer 
with ARNT. The heterodimer binds to the XRE and alters 
expression of genes, leads to RNA Polymerase-II 
recruitment and gene transcription. In addition, AhR can 
affect cellular signaling through interactions with various 
regulatory and signaling proteins, including PKC and tyrosine 
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Kinase, MAPK pathways, in which inhibitors of these kinases 
block the induction of CYP1A1. AhR also interacts with other 
signaling pathways that are mediated by estrogen receptor 
and glucocorticoid receptor, and involves in cell-cycle 
regulation through growth factor signaling, if AhR activation 
refers to cell-cycle arrest. AhR have been implicated in the 
initiation and progression of cancers in multiple organs. In 
addition to environmental factors, genetic factor can modify 
CYP1A1 expression. Genetic polymorphisms in CYP1A1 
determine the different susceptibilities of individual humans 
to carcinogenesis caused by the action of PAHs. Further 
study is needed to define the impact of variant forms of 
CYP1A1 on the incidence of cancers in humans. 
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